Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia
Objective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007120304214 |
id |
doaj-0223f87e617a4ad08b1642dd7d72ffb5 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Takashi Ishiguro Kenji Takano Naho Kagiyama Chiaki Hosoda Yoichi Kobayashi Yotaro Takaku Naomi Takata Miyuki Ueda Yasuhiro Morimoto Keisuke Kasuga Ryota Ozawa Taisuke Isono Takashi Nishida Eriko Kawate Yasuhito Kobayashi Yoshihiko Shimizu Kazuyoshi Kurashima Tsutomu Yanagisawa Noboru Takayanagi |
spellingShingle |
Takashi Ishiguro Kenji Takano Naho Kagiyama Chiaki Hosoda Yoichi Kobayashi Yotaro Takaku Naomi Takata Miyuki Ueda Yasuhiro Morimoto Keisuke Kasuga Ryota Ozawa Taisuke Isono Takashi Nishida Eriko Kawate Yasuhito Kobayashi Yoshihiko Shimizu Kazuyoshi Kurashima Tsutomu Yanagisawa Noboru Takayanagi Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia Respiratory Medicine Case Reports COVID-19 Novel coronavirus 2019 Pneumonia SARS-CoV-2 Wuhan |
author_facet |
Takashi Ishiguro Kenji Takano Naho Kagiyama Chiaki Hosoda Yoichi Kobayashi Yotaro Takaku Naomi Takata Miyuki Ueda Yasuhiro Morimoto Keisuke Kasuga Ryota Ozawa Taisuke Isono Takashi Nishida Eriko Kawate Yasuhito Kobayashi Yoshihiko Shimizu Kazuyoshi Kurashima Tsutomu Yanagisawa Noboru Takayanagi |
author_sort |
Takashi Ishiguro |
title |
Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia |
title_short |
Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia |
title_full |
Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia |
title_fullStr |
Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia |
title_full_unstemmed |
Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia |
title_sort |
clinical course and findings of 14 patients with covid-19 compared with 5 patients with conventional human coronavirus pneumonia |
publisher |
Elsevier |
series |
Respiratory Medicine Case Reports |
issn |
2213-0071 |
publishDate |
2020-01-01 |
description |
Objective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with cHCoV pneumonia admitted to our institution and treated up to March 8, 2020, were retrospectively analyzed. Results: On admission, 10 patients had pneumonia, 5 of whom had pulmonary shadows detectable only via computed tomography (CT). During hospitalization, another patient with no pulmonary shadows on admission developed pneumonia. In total, 11 (78.6%) of the 14 patients developed pneumonia, indicating its high prevalence in COVID-19. During hospitalization, the patients' symptoms spontaneously relapsed and resolved, and gastrointestinal symptoms were frequently found. C-reactive protein values showed correlation with the patients’ clinical courses. Ritonavir/lopinavir were administered to 5 patients whose respiratory conditions worsened during admission, all of whom improved. However, the pneumonia in the 6 other patients improved without antivirals. None of the 14 patients died, whereas 5 other patients with cHCoV pneumonia were in respiratory failure on admission, and one patient (20%) died. Conclusion: Both SARS-CoV-2 and cHCoV can cause severe pneumonia. Problems for future resolution include whether antiviral agents administered in cases of mild or moderate severity can reduce the number of severe cases, and whether antivirals administered in severe cases can reduce mortality. |
topic |
COVID-19 Novel coronavirus 2019 Pneumonia SARS-CoV-2 Wuhan |
url |
http://www.sciencedirect.com/science/article/pii/S2213007120304214 |
work_keys_str_mv |
AT takashiishiguro clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT kenjitakano clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT nahokagiyama clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT chiakihosoda clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT yoichikobayashi clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT yotarotakaku clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT naomitakata clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT miyukiueda clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT yasuhiromorimoto clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT keisukekasuga clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT ryotaozawa clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT taisukeisono clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT takashinishida clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT erikokawate clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT yasuhitokobayashi clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT yoshihikoshimizu clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT kazuyoshikurashima clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT tsutomuyanagisawa clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia AT noborutakayanagi clinicalcourseandfindingsof14patientswithcovid19comparedwith5patientswithconventionalhumancoronaviruspneumonia |
_version_ |
1724380354175827968 |
spelling |
doaj-0223f87e617a4ad08b1642dd7d72ffb52020-12-17T04:48:38ZengElsevierRespiratory Medicine Case Reports2213-00712020-01-0131101207Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumoniaTakashi Ishiguro0Kenji Takano1Naho Kagiyama2Chiaki Hosoda3Yoichi Kobayashi4Yotaro Takaku5Naomi Takata6Miyuki Ueda7Yasuhiro Morimoto8Keisuke Kasuga9Ryota Ozawa10Taisuke Isono11Takashi Nishida12Eriko Kawate13Yasuhito Kobayashi14Yoshihiko Shimizu15Kazuyoshi Kurashima16Tsutomu Yanagisawa17Noboru Takayanagi18Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan; Corresponding author. 1696 Itai, Saitama, 360, Japan.Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Pathology, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Pathology, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Radiology, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Radiology, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, JapanObjective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with cHCoV pneumonia admitted to our institution and treated up to March 8, 2020, were retrospectively analyzed. Results: On admission, 10 patients had pneumonia, 5 of whom had pulmonary shadows detectable only via computed tomography (CT). During hospitalization, another patient with no pulmonary shadows on admission developed pneumonia. In total, 11 (78.6%) of the 14 patients developed pneumonia, indicating its high prevalence in COVID-19. During hospitalization, the patients' symptoms spontaneously relapsed and resolved, and gastrointestinal symptoms were frequently found. C-reactive protein values showed correlation with the patients’ clinical courses. Ritonavir/lopinavir were administered to 5 patients whose respiratory conditions worsened during admission, all of whom improved. However, the pneumonia in the 6 other patients improved without antivirals. None of the 14 patients died, whereas 5 other patients with cHCoV pneumonia were in respiratory failure on admission, and one patient (20%) died. Conclusion: Both SARS-CoV-2 and cHCoV can cause severe pneumonia. Problems for future resolution include whether antiviral agents administered in cases of mild or moderate severity can reduce the number of severe cases, and whether antivirals administered in severe cases can reduce mortality.http://www.sciencedirect.com/science/article/pii/S2213007120304214COVID-19Novel coronavirus 2019PneumoniaSARS-CoV-2Wuhan |